Get Taysha Gene Therapies alerts:View Our Latest Research Report on Taysha Gene TherapiesTaysha Gene Therapies Trading Down 2.8%NASDAQ:TSHA opened at $3.16 on Friday. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year. About Taysha Gene Therapies(Get Free Report)Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Read MoreReceive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.